US2006257371A1PendingUtilityA1

Adenoviral vectors for treating diseases

61
Assignee: ONYX PHARMACEUTICALSPriority: Apr 24, 1998Filed: Jul 17, 2006Published: Nov 16, 2006
Est. expiryApr 24, 2018(expired)· nominal 20-yr term from priority
A61K 38/217C12N 2710/10332A61K 38/191A61K 38/1761A61K 38/20C12N 15/86A61K 35/761A61K 38/195A61K 48/00C12N 2710/10343
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous adenoviral transcriptional control sequences will exhibit an expression pattern, both in terms of timing and degree of expression, similar to the endogenous adenoviral gene(s) that it replaces, and further optionally including mutations in other parts of the adenoviral genome, including certain E1B or E1A regions, and that have applications for diagnosing or treating disease, preferably disease involving unwanted cell growth, including cancer.

Claims

exact text as granted — not AI-modified
1 .- 6 . (canceled)  
     
     
         7 . A composition of matter comprising an adenoviral vector selected from the group consisting of pGE3SV, pGE3SV+V, pGE3SV+B, and pGE3SV+V+B.  
     
     
         8 . A composition of matter comprising an adenovirus selected from the group consisting of E3SV, E3SV+V, E3SV+B, and E3SV+V+B.  
     
     
         9 .- 14 . (canceled)  
     
     
         15 . Cells comprising said adenoviral vectors of  claim 7 .  
     
     
         16 . Cells comprising said adenoviruses of  claim 8 .  
     
     
         17 - 27 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.